Mallinckrodt Public Limited Company and U.S. Federal Trade Commission closed Legacy Questcor Matter with company agreement to license Synacthen(R) Depot for possible U.S. development in two indications and cash settlement payment of $100 million. Mallinckrodt retains rights to continue U.S. development of product for all other indications, including potential use in treatment of Duchenne Muscular Dystrophy (DMD); continues to own rights to product outside the U.S.